tiprankstipranks
Analyst Profile
Followed by 550 other investors
.
Leland Gershell

Leland Gershell

Oppenheimer
Wall Street Analyst
Ranked #7,457 out of 8,040 Analysts on TipRanks (#20,090 out of 21,629 overall experts)

Success Rate

37%
134 out of 361 Profitable Transactions

Average Return

-3.70%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Leland Gershell's ratings since 2019 and opened each position for the duration of 1 Year:
37.12% of your transactions would have been profitable with an average return of -3.7%

Stock Rating Distribution

543Ratings
81.40% Buy
17.86% Hold
0.74% Sell
Distribution of Leland Gershell's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Agile Therapeutics
(AGRX)
Rating Type:Buy
Dates:Oct 29, 2019 - Oct 29, 2020
Gain:698.70%
The most profitable rating made by Leland Gershell

Leland Gershell's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
First Wave Bio
Apr 03, 2019
Buy
Reiterated
$8.00
(5064.62% Upside)
0%
-60.97%
9
Acelrx
May 09, 2019
Hold
Assigned
0.00%
9
MEI Pharma
May 10, 2019
Buy
Reiterated
$7.00
(1196.06% Upside)
0%
-36.07%
3
EPZM
Epizyme
Jul 31, 2020
Hold
Assigned
60%
+2.94%
10
Evofem Biosciences
Sep 11, 2020
Hold
Assigned
55%
+20.95%
15
Catalyst Pharma
Oct 09, 2020
Hold
Assigned
57%
+16.53%
19
Amarin
Dec 31, 2020
Hold
Assigned
100%
+80.33%
13
Societal CDMO
Dec 31, 2020
Hold
Assigned
50%
+23.18%
17
Outlook Therapeutics
Dec 31, 2020
Hold
Assigned
71%
+25.64%
9
ADMA Biologics
Dec 31, 2020
Hold
Assigned
19%
-17.69%
22
List of latest recommendations made by Leland Gershell. Click to expand and see Leland Gershell's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More